Inventor
Michael Ochse
Inventor
Ludwigshafen, DE
Overview
Patents· 38 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds38%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations36%
A61KPreparations for medical, dental or toiletry purposes13%
C07CAcyclic or carbocyclic compounds10%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
PatentTitleYear
10,556,907Fused heterocyclic compounds as S1P modulators202010,556,914Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use202010,308,610Inhibitor compounds of phosphodiesterase type 10A201910,280,159Fused (hetero)cyclic compounds as S1P modulators201910,155,770Substituted pyrazolopyrimidines and method of use20189,938,269Inhibitor compounds of phosphodiesterase type 10A20189,856,220'Inhibitor compounds of phosphodiesterase type 10A'20189,828,381Substituted pyrazolopyrimidines and method of use20179,790,203'Inhibitor compounds of phosphodiesterase type 10A'20179,657,034'Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors'20179,475,808'Inhibitor compounds of phosphodiesterase type 10A'20169,475,782'Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors'20169,464,085'Inhibitor compounds of phosphodiesterase type 10A'20169,388,180'Inhibitor compounds of phosphodiesterase type 10A'20169,365,512'Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy'20169,309,200'Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy'20169,296,697'Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors'20169,273,068'Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A'20169,238,619'Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy'20169,227,930'Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy'20169,200,005'Inhibitor compounds of phosphodiesterase type 10A'20159,163,019'Inhibitor compounds of phosphodiesterase type 10A'20159,096,619'Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy'20159,067,871'Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy'20159,051,280'Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy'20159,045,459'Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy'20158,957,089'Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy'20158,921,406'5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors'20148,883,839'Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy'20148,877,794'Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy'20148,846,743'Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy'20148,686,002'Heterocyclic compounds and their use as binding partners for 5-HT5 receptors'20148,653,100'Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy'20148,642,587'Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy'20148,563,617'Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy'20138,481,576'Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors'20138,431,604'Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors'20138,420,670'4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy'2013Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2013–2020Patents assigned to ABBVIE DEUTSCHLAND (34)· patent assignee history
2013–2018Patents assigned to OCHSE MICHAEL (16)· patent assignee history
2013–2016Patents assigned to AMBERG WILHELM (15)· patent assignee history
2013–2016Patents assigned to LANGE UDO (14)· patent assignee history
2013–2020Based in Ludwigshafen, DE· patent location history
2013–2014Based in Bad Duerkheim, DE· patent location history
2014–2020Patents assigned to ABBVIE INC (25)· patent assignee history
2014–2017Based in Wiesbaden, DE· patent location history
2014Based in Weisenheim, DE· patent location history
2016Based in Bad Durkheim, DE· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ABBVIE DEUTSCHLAND | 34 | 2013–2020 |
| ABBVIE INC | 25 | 2014–2020 |
| OCHSE MICHAELself | 16 | 2013–2018 |
| AMBERG WILHELM | 15 | 2013–2016 |
| LANGE UDO | 14 | 2013–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Ludwigshafen, DE | 25 | 2013–2020 |
| Wiesbaden, DE | 7 | 2014–2017 |
| Bad Durkheim, DE | 2 | 2016 |
| Bad Duerkheim, DE | 2 | 2013–2014 |
| Weisenheim, DE | 1 | 2014 |